Global Scans · Psoriasis · Weekly Summary

• [New] Denmark's Union Therapeutics A/S has begun a strategic collaboration with Innovent Biologics, Inc., over orismilast, a next-generation oral PDE4 inhibitor for inflammatory dermatology conditions that could compete directly with Amgen Inc.'s psoriasis blockbuster Otezla. Bioworld
• The autoimmune diseases segment is likely to register a fastest CAGR of 14.2% from 2026 to 2034 owing to the rising prevalence of conditions such as rheumatoid arthritis psoriasis and inflammatory bowel disease which require long term biological management. Market Data Forecast

Last updated: 22 June 2026